CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction-Reference-Cited by-同舟云学术

CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction

Published:2020-03 Issue:3 Volume:2 Page:e116-e128
ISSN:2589-7500
Container-title:The Lancet Digital Health
language:en
Short-container-title:The Lancet Digital Health

Author:

Vaidya Pranjal,Bera Kaustav,Gupta Amit,Wang Xiangxue,Corredor Germán,Fu Pingfu,Beig Niha,Prasanna Prateek,Patil Pradnya D,Velu Priya D,Rajiah Prabhakar,Gilkeson Robert,Feldman Michael D,Choi Humberto,Velcheti Vamsidhar,Madabhushi Anant

Funder

National Cancer Institute

National Center for Research Resources

Department of Veterans Affairs Biomedical Laboratory Research and Development Service

DOD Prostate Cancer Idea Development Award

Publisher

Elsevier BV

Subject

Health Information Management,Decision Sciences (miscellaneous),Health Informatics,Medicine (miscellaneous)

Reference28 articles.

1. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer;Goldstraw;J Thorac Oncol,2016

2. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition);Scott;Chest,2007